Salim Amrani, MD
Colon & Rectal Surgery · Augusta, GANPI 1295983195
Payments from drug & device makers
What this record shows
This record is dominated by education: $5,500 of the $7,713 with a category attached, or 71.3%. Intuitive Surgical accounts for 90.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $6,575 and has fallen 88.6% since, to $750 in 2025.
Across 29 payments — averaging $265.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Biom'up SA$196
- Dilon Technologies, Inc.$174
- Prescient Surgical$131
- Johnson & Johnson$76
- Takeda Pharmaceuticals U.S.A., Inc.$48
- plus $110 from 6 others
What the payments were for
- Travel & lodging$5337%
- Food & beverage$1,68022%
- Education$5,50071%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 17 | $6,978 |
| Biom'up SA | 1 | $196 |
| Dilon Technologies, Inc. | 1 | $174 |
| Prescient Surgical | 1 | $131 |
| Johnson & Johnson | 1 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Acera Surgical, Inc. | 1 | $27 |
| THD America, Inc. | 1 | $22 |
| Axonics, Inc. | 1 | $18 |
| AbbVie | 1 | $16 |
| TELA Bio, Inc. | 1 | $15 |
| Smith+Nephew | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$5,500
- Da Vinci Surgical System$1,041
- HEMOBLAST$196
- HemoBlast Bellows$174
- CleanCision$131
How this compares
$7,713 in reported general payments places this provider in the 65th percentile of 66 colon & rectal surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 44 | $768 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 15 | $309 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 13 | $233 |
| Metronidazole | 20 | $93 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $92 |
| Neomycin Sulfate | 13 | $42 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Augusta
- Ankur GoelAugusta$19K
- Nathalie Mantilla FarfanAugusta$17K
- Katherine BaysingerAugusta$16K
- Barry JenkinsAugusta$3K
- John CheapeAugusta$2K
- Mallory LawrenceAugusta$707
- David ArmstrongLawrenceville$1.2M
- Jeffrey CohenMarietta$663K
- Erin King-MullinsMacon$119K
- Jay SinghRoswell$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.